New trial aims to find safer chemo for stem cell transplants in leukemia patients
NCT ID NCT07025824
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in 220 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see which drug works better at helping patients survive longer with fewer side effects. Participants will receive one of the two drugs along with fludarabine, and researchers will track survival, remission, and complications like graft-versus-host disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Treosulfan and Melphalan (chemotherapy drugs)
What this could lead to
If it works, this could show that treosulfan is a better option than melphalan for preparing patients with AML or MDS for a stem cell transplant, potentially improving survival and reducing complications.
What could go wrong
This is a phase 2 trial with 220 participants, so results are still early. The drugs may cause serious side effects like infections or graft-versus-host disease, and the study may not show a clear benefit for treosulfan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I
Dresden, Germany
Contact
-
Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum
Münster, Germany
Contact
-
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, Germany
Contact
-
Universitätsmedizin Halle (Saale)
Halle, Germany
Contact